Management

This page includes content on healthcare management, including health system, hospital, department and clinic business management and administration. Areas of focus are on cardiology and radiology department business administration. Subcategories covered in this section include healthcare economics, reimbursement, leadership, mergers and acquisitions, policy and regulations, practice management, quality, staffing, and supply chain.

RSS icon
Thumbnail

CVS, Aetna shareholders approve $69B acquisition

Shareholders for both CVS Health and Aetna overwhelmingly approved the proposed $69 billion deal for CVS to acquire the health insurer, bringing the merger one step closer to completion.

ACA stabilization package would boost coverage, lower premiums on individuals

A pair of bills to fund the Affordable Care Act (ACA)’s cost-sharing reduction (CSR) subsidies and create a new reinsurance program would lower monthly premiums for exchange plans by 20 to 40 percent and boost enrollment by 3.2 million people. Conservative groups, however, call the legislation a “bailout” for insurance companies.

Thumbnail

Leadership team announced for merged Advocate-Aurora system

With Milwaukee’s Aurora Health Care and Chicago’s Advocate Healthcare expecting to clear the final regulatory hurdle for their proposed merger, the two have lined up the leadership team that will report to the co-CEOs of the new system.

Thumbnail

Congress wants more info on Joint Commission accreditation process

The House and Energy Commerce Committee has sent letters to CMS and four hospital accreditation organizations (AOs), including the Joint Commission, asking for more information on how the entities conduct surveys and why there’s been a disconnect between their results and what state survey agencies find.

CMS didn’t reject ‘our approach’ to ACA, argues Idaho’s governor

When CMS told Idaho it couldn’t move ahead with plans to allow health insurers to offer coverage which doesn’t comply with the Affordable Care Act (ACA), Idaho Gov. Butch Otter didn’t see it as a rejection but rather the start of a negotiation.

Thumbnail

CMS: Quality measure changes coming this year

Providers should expect to see some concrete action taken soon on reducing the burden of quality reporting, according to a CMS presentation on the agency’s “Meaningful Measures” initiative at the HIMSS18 conference in Las Vegas.

Moody’s reports medical device industry may see up to 5% growth

The future of the medical products and device industry is brightening, according to Moody’s investors Service, which upgraded its outlook from stable to positive. Moody’s predicts “continued product innovation” and synergies from acquisitions will drive growth of earnings before interest, depreciation and amortization (EBITDA) of between 4 and 5 percent over the next 12 to 18 months.

Medical device industry may see up to 5% growth

Moody’s Investors Service has upgraded the financial outlook for the medical products and device industry from stable to positive, predicting that “continued product innovation” and synergies from acquisitions will drive growth of earnings before interest, depreciation and amortization (EBITDA) of between 4 and 5 percent over the next 12 to 18 months.

Displaying 3729 - 3736 of 6654

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup